For men undergoing radiation therapy following prostatectomy, the addition of hormone therapy may not significantly improve survival rates, according to a recent study. The research, presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium in February 2026, suggests that the benefits of hormone therapy are largely confined to patients with higher prostate-specific antigen (PSA) levels before the start of radiation. These findings underscore the need for a more personalized approach to treatment, potentially avoiding unnecessary side effects and improving quality of life for many patients.
Prostate cancer remains a significant health concern globally, with over 1.4 million new cases diagnosed in 2020. Estimates suggest a substantial increase to nearly 2.9 million cases annually by 2040, driven by aging populations and increased PSA testing. While hormone therapy has proven effective when combined with radiation for men who haven’t had surgery, its role in post-operative radiation treatment has been less clear. This new research aims to clarify that distinction, offering a more nuanced understanding of treatment efficacy.
Understanding the Study and its Findings
The study, coordinated by specialists at UCLA Health Jonsson Comprehensive Cancer Center, involved a meta-analysis of data from over 6,000 men enrolled in six randomized clinical trials. Researchers analyzed data from patients who received either radiation therapy alone or radiation therapy combined with hormone therapy – either short-term (4-6 months) or long-term (24 months) – after undergoing prostatectomy. Patients were followed for a median of nine years, allowing for assessment of overall survival, survival without metastasis, and recurrence rates. The analysis leveraged individual patient data to examine the influence of pre-radiation PSA levels on treatment outcomes.
The results revealed that at 10 years, 83.6% of men treated with radiation therapy alone were still alive, compared to 84.3% of those who received radiation therapy in combination with hormone therapy. This difference, while present, was relatively small. Crucially, the impact of hormone therapy varied significantly based on initial PSA levels. For men with low PSA levels (≤0.5 ng/mL) before radiation, adding hormone therapy provided no discernible survival benefit. Although, patients with higher PSA levels did experience modest improvements in both survival and freedom from metastasis, suggesting that the benefits of hormone therapy are primarily limited to those at higher risk of recurrence.
The Role of PSA in Treatment Decisions
Prostate-specific antigen (PSA) is a protein produced by the prostate gland. Elevated PSA levels can indicate the presence of prostate cancer, but can also be caused by other conditions, such as benign prostatic hyperplasia (BPH) or prostatitis. Determining PSA levels is a critical first step in assessing a man’s risk of prostate cancer and guiding treatment decisions. The study’s findings highlight the importance of considering PSA levels when determining whether to add hormone therapy to post-operative radiation treatment.
The duration of hormone therapy also appeared to play a role, though a less pronounced one. Short-term hormone therapy did not improve overall survival but did slightly reduce the risk of cancer spreading. Long-term therapy was associated with a small survival benefit, particularly in patients with elevated PSA levels after prostatectomy. However, extending hormone therapy for a longer duration did not provide any additional survival advantage, while potentially increasing the risk of side effects.
Weighing the Benefits and Risks of Hormone Therapy
Hormone therapy, also known as androgen deprivation therapy (ADT), works by reducing the levels of testosterone in the body, which can slow the growth of prostate cancer cells. However, ADT is not without its drawbacks. Common side effects include fatigue, hot flashes, sexual dysfunction, weight gain, bone loss, and metabolic changes that can increase the risk of cardiovascular disease. These side effects can significantly impact a patient’s quality of life.
The study’s authors emphasize that the findings support a more personalized approach to treatment. For many men who have undergone prostatectomy and have low, but detectable, PSA levels, radiation therapy alone may be sufficient. Avoiding unnecessary hormone therapy in these cases could spare patients months of debilitating side effects without compromising their survival. This approach aligns with a growing trend in cancer care towards precision medicine, tailoring treatment to the individual characteristics of each patient and their disease.
Ongoing Research and Future Directions
Researchers are continuing to investigate ways to better identify which patients will benefit most from hormone therapy after prostatectomy. The ongoing BALANCE study, mentioned in the research, aims to identify biomarkers that can help predict treatment response. Biomarkers are measurable substances in the body that can indicate the presence of a disease or the body’s response to treatment. Identifying reliable biomarkers could allow clinicians to more accurately select patients who are likely to benefit from hormone therapy, maximizing its effectiveness while minimizing unnecessary side effects.
The findings from this meta-analysis, published in The Lancet and presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium, represent a significant step forward in our understanding of post-operative prostate cancer treatment. They reinforce the importance of individualized treatment plans based on a comprehensive assessment of each patient’s risk factors and disease characteristics.
Key Takeaways
- Hormone therapy added to radiation after prostate surgery doesn’t improve survival for most men.
- The benefit of hormone therapy is limited to patients with higher pre-treatment PSA levels.
- Short-term hormone therapy offers limited benefits, while long-term therapy may provide a small survival advantage in specific cases.
- Avoiding unnecessary hormone therapy can reduce side effects and improve quality of life for many patients.
- Ongoing research is focused on identifying biomarkers to better predict treatment response.
As research continues to refine our understanding of prostate cancer and its treatment, it’s crucial for patients to engage in open and honest conversations with their healthcare providers to determine the most appropriate course of action. The goal is to achieve the best possible outcome while minimizing the impact on quality of life. Further updates on prostate cancer treatment guidelines and research findings will likely be presented at future meetings of the American Society of Clinical Oncology and published in leading medical journals.
Do you have questions about prostate cancer treatment options? Share your thoughts in the comments below, and please consider sharing this article with anyone who might find it helpful.
Keep reading